Cirrhosis

Cirrhosis is a condition in which the liver slowly deteriorates and malfunctions due to chronic injury. Scar tissue replaces healthy liver tissue, partially blocking the flow of blood through the liver.

What is Cirrhosis?

Cirrhosis is a severe form of liver disease wherein normal liver tissue is replaced by scar tissue (fibrous tissue).

What Causes Cirrhosis?

Managing and Treating Cirrhosis

Liver Disease Symptoms

AHCC supplement shows potential in protecting the liver from fibrosis

Chronic liver damage can lead to hepatitis, which causes fibrosis of the liver. This buildup of collagen and other fibrous tissue accelerates when hepatic stellate cells become activated during hepatitis, often resulting in liver cancer or cirrhosis, both of which can be fatal.

19 Dec 2024

New drug approach shows promise in treating metabolic liver diseases

A MedUni Vienna study has identified a new approach to the drug treatment of metabolic liver diseases. In an experimental study, pharmacological inhibition of an enzyme that plays a central role in fat metabolism promoted liver health reduced liver fat, inflammation and fibrotic remodeling (connective tissue scarring).

18 Dec 2024

Revolutionizing MASLD treatment with GLP-1 receptor agonists

Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic dysfunction-associated steatotic liver disease.

16 Dec 2024

A novel approach to prevent severe liver disease in diabetes

New research from Karolinska Institutet in Sweden highlights the possibility of screening people with type 2 diabetes for liver damage at the same time as they undergo screening for eye disease. The study is published in Lancet Gastroenterology and Hepatology.

13 Dec 2024

New hepatitis B vaccine offers superior protection for people with HIV

A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody response among people living with HIV who didn't respond to prior vaccination, according to the results of an international study led by a Weill Cornell Medicine investigator.

11 Dec 2024

Systematic review and meta-analysis of coronary artery disease in liver cirrhosis

Coronary artery disease (CAD) is increasingly observed in patients with liver cirrhosis. However, data on the incidence and prevalence of CAD in cirrhotic patients are heterogeneous, and the association remains uncertain.

10 Dec 2024

Two distinct types of fatty liver disease identified

Researchers at Karolinska Institutet and the University of Gothenburg have identified two types of metabolic-associated fatty liver disease - a liver-specific type and a systemic type that affects other organs and tissues.

10 Dec 2024

Tea, apples, and chocolate proven to support liver health

A flavonoid-rich diet, including apples, tea, and dark chocolate, significantly lowers the risk of non-alcoholic fatty liver disease (NAFLD) and improves liver health biomarkers. These findings highlight the potential of dietary flavonoids in combating liver fat accumulation and inflammation.

9 Dec 2024

Two new subtypes of MASH revealed with different risks and outcomes

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), impacts roughly 30% of the global adult population.

9 Dec 2024

New vaccine approach shows promise against Hepatitis C

Globally, approximately 58 million people are chronically infected with HCV, resulting in 290,000 annual deaths due to complications such as liver cirrhosis and liver cancer.

6 Dec 2024

Disrupted sleep-wake rhythms linked to liver disease progression

The prevalence of MASLD (metabolic dysfunction-associated steatotic liver disease) is exploding in most regions of the world, boosted by increased obesity and sedentary lifestyles. MASLD (formerly known as non-alcoholic fatty liver disease) is already the most common liver disorder: it affects 30% of adults and between 7% and 14% of children and adolescents, and this prevalence is predicted to rise to more than 55% of adults by 2040.

4 Dec 2024

Disrupted sleep patterns identified in patients with metabolic dysfunction-associated steatotic liver disease

The prevalence of MASLD (metabolic dysfunction-associated steatotic liver disease) is exploding in most regions of the world, boosted by increased obesity and sedentary lifestyles.

2 Dec 2024

Expert explores the expanding applications of GLP1 therapies

Researchers review recent advancements in glucagon-like peptide-1-based therapies.

28 Nov 2024

Innovative tool enhances the accuracy of predicting survival outcomes for liver failure patients

Researchers have unveiled a groundbreaking advancement in liver failure care: the CATCH-LIFE-MELD score (Chinese Acute-on-Chronic Liver Failure Consortium (CATCH-LIFE)-MELD score).

26 Nov 2024

Groundbreaking research sheds light on mitochondrial DNA depletion syndrome

Mitochondrial DNA depletion syndrome (MTDPS) is a rare genetic disorder characterized by a marked decrease in mitochondrial DNA (mtDNA).

25 Nov 2024

Mursla Bio's EvoLiver surpasses current standards in liver cancer surveillance, data presented at AASLD Liver Meeting 2024

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of dynamic biopsy technology, today announced results of its multi-center clinical study, MEV01, in collaboration with leading academic institutes including University College London, Imperial College London, University Hospital of Santa Maria and the Medical University of Graz.

From Mursla Bio 25 Nov 2024